As the range of disease states associated with the gut microbiome expands – and the mechanistic links between the gut microbiome and host physiology further deepens – so interest also grows in microbiome manipulation as medical therapy. In particular, bolstered by its established role in recurrent C. difficile infection (and promising results in other conditions), faecal microbiota transplant (FMT) has remained of growing global focus. This article reviews the key FMT-based studies published between April 2020-March 2021. While the COVID-19 pandemic was the dominant challenge of the year, important FMT trials of interest were published for patients with a range of different conditions. The emergence of ‘next generation’ microbiome therapeutics offers an additional perspective and new opportunities within the field.
To cite this article
Microbiota and faecal microbiota transplant
Microb Health Dis 2021;
Submission date: 31 Mar 2021
Revised on: 06 Apr 2021
Accepted on: 12 Apr 2021
Published online: 09 Sep 2021
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.